As numerous ion channel blockers and openers are already approved for human use for arrhythmias, epilepsy, etc., future efforts at identifying novel and more specific HCN2 drugs may be warranted, as part of a strategy to identify useful electroceuticals (Churchill et al., 2019). The gene discussed is HCN2; the disease is epilepsy.